Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Turner, Hugo C ^a   Baussano, Iacopo ^b   Garnett, Geoff P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER PREVENTION; CHILD; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE TRANSMISSION; EXPOSURE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INNATE IMMUNITY; MODEL; PAPILLOMAVIRUS INFECTION; REINFECTION; SCHOOL CHILD; UNITED KINGDOM; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; WOMEN'S HEALTH;

ADOLESCENT; ADULT; AGED; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; MODELS, ECONOMIC; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION; YOUNG ADULT;

EID: 84884644275     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075552     Document Type: Article

References (42)

1. World Health Organization (2010) United Kingdom; Human Papillomavirus and Related Cancers, Fact Sheet 2010. Barcelona: WHO/ICO Information Centre on HPV and Cervical Cancer.
2. Parkin DM, (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118: 3030-3044. doi:10.1002/ijc.21731. PubMed: 16404738.
3. Lévy-Bruhl D, Bousquet V, King LA, O'Flanagan D, Bacci S, et al. (2009) The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey. Eur J Cancer 45: 2709-2713. doi:10.1016/j.ejca.2009.07.023. PubMed: 19695863.
4. JCVI (2008) Statement on HPV vaccination. Available: www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_094739.pdf. Accessed 2013 February 2.
5. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, et al. (2007) Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56: 1-24. PubMed: 17380109.
6. Department of Health (2011) nnual HPV vaccine coverage in England in 2009/2010. (15439). Available: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123795 Accessed 2013 February 2). PubMed: 22077414.
7. Rondy M, van Lier A, van de Kassteele J, Rust L, de Melker H, (2010) Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine 28: 2070-2075. doi:10.1016/j.vaccine.2009.12.042. PubMed: 20045095.
8. Kim JJ, Ortendahl J, Goldie SJ, (2009) Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 151: 538-545. doi:10.7326/0003-4819-151-8-200910200-00007. PubMed: 19841455.
9. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM, (2007) Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine 26: 128-139. doi:10.1016/j.vaccine.2007.10.056. PubMed: 18055075.
10. Kim JJ, Goldie SJ, (2008) Health and Economic Implications of HPV Vaccination in the United States. N Engl J Med 359: 821-832. doi:10.1056/NEJMsa0707052. PubMed: 18716299.
11. Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, et al. (2008) Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 26: 5654-5661. doi:10.1016/j.vaccine.2008.07.098. PubMed: 18723068.
12. Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E, (2009) Age-based programs for vaccination against HPV. Value Health 12: 697-707. doi:10.1111/j.1524-4733.2009.00512.x. PubMed: 19490561.
13. Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, et al. (2012) Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 131: 106-116. doi:10.1002/ijc.26362. PubMed: 21858807.
14. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, et al. (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 105: 28-37. doi:10.1038/bjc.2011.185. PubMed: 21629249.
15. Jit M, Choi YH, Edmunds WJ, (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769. doi:10.1136/bmj.a769. PubMed: 18640957.
16. Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, et al. (2011) Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis 204: 377-384. doi:10.1093/infdis/jir281. PubMed: 21742836.
17. Jit M, Chapman R, Hughes O, Choi YH, (2011) Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 343: d5775. doi:10.1136/bmj.d5775. PubMed: 21951758.
18. Bogaards JA, Coupé VM, Meijer CJ, Berkhof J, (2011) The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine 29: 8929-8936. doi:10.1016/j.vaccine.2011.09.055. PubMed: 21945961.
19. Office for National Statistics (2008) Population Estimates for UK, England and Wales, Scotland and Northern Ireland, mid 2008. Available: http://www.ic.nhs.uk/statistics-and-data-collections/screening/cervicalscreening/cervical-screening-programme-england-2009-10. Accessed 2013 February 2.
20. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, et al. (2006) HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95: 56-61. doi:10.1038/sj.bjc.6603210. PubMed: 16773068.
21. Department of Health Statistical Bulletin, (2010) Cervical screening programme, England: 2009-10. The Information Centre.
22. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, et al. (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111: 278-285. doi:10.1002/ijc.20244. PubMed: 15197783.
23. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, et al. (2009) Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374: 301-314. doi:10.1016/S0140-6736(09)61248-4. PubMed: 19586656.
24. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 100-110. doi:10.1016/S1470-2045(11)70287-X. PubMed: 22075170.
25. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, et al. (2011) Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 103: 1444-1451. doi:10.1093/jnci/djr319. PubMed: 21908768.
26. NHS (2013) How is the HPV vaccine given? Available: http://www.nhs.uk/Conditions/vaccinations/Pages/how-is-hpv-vaccine-cervarix-gardasil-given.aspx. Accessed 2013 March 10.
27. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, et al. (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298: 743-753. doi:10.1001/jama.298.7.743. PubMed: 17699008.
28. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, et al. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13: 89-99. doi:10.1016/S1470-2045(11)70286-8. PubMed: 22075171.
29. National Institute for Health and Clinical Excellence (2013) Measuring effectiveness and cost effectiveness: the QALY. Available: http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp. (Accessed 2nd August 2013).
30. National Institute for Health Clinical Excellence, (2004) uide to the methods of technology appraisal (reference N0515). Available: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf Accessed 2013 February 2.
31. Myers E, Green S, Lipkus IP, (2004) Patient preferences for health states related to HPV infection: visual analogue scales versus time trade-off elicitation. Proceedings of the 21st International Papillomavirus Conference, Mexico City, Mexico.
32. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, et al. (2004) Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine. J Natl Cancer Inst 96: 604-615. doi:10.1093/jnci/djh104. PubMed: 15100338.
33. Brown RE, Breugelmans JG, Theodoratou D, Bénard S, (2006) Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 22: 663-670. doi:10.1185/030079906X99972. PubMed: 16684427.
34. Curtis L, (2005) nit costs of health and social care 2005. University of Kent at Canterbury: Personal. Social Services Research Unit.
35. Wolstenholme JL, Whynes DK, (1998) Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 34: 1889-1893. doi:10.1016/S0959-8049(98)00232-9. PubMed: 10023311.
36. Wallace LA, Young D, Brown A, Cameron JC, Ahmed S, et al. (2005) Costs of running a universal adolescent hepatitis B vaccination programme. Vaccine 23: 5624-5631. doi:10.1016/j.vaccine.2005.06.034. PubMed: 16099079.
37. Curtis L, (2007) nit costs of health and social care 2007. University of Kent at Canterbury: Personal. Social Services Research Unit.
38. British, Medical Association, the Royal Pharmaceutical Society of Great Britain (2010) British National Formulary. BMA 59.
39. Choi YH, Jit M, Gay N, Cox A, Garnett GP, et al. (2010) Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 28: 4091-4102. doi:10.1016/j.vaccine.2009.09.125. PubMed: 19909831.
40. Handbook on Cancer Prevention IARC, (2005) Cervix Cancer Screening Lyon: IARC Press.
41. Salisbury DM, (2012) Male vaccination against human papillomavirus. Lancet Infect Dis 12: 582-583. doi:10.1016/S1473-3099(12)70082-8. PubMed: 22835890.
42. Health Protection Agency (2012) Human papillomavirus (HPV)- cervical cancer and genital warts. Available: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/GenitalWarts/. Accessed 2013 February 2.